Results 11 to 20 of about 319 (119)

Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of Talaromyces marneffei. [PDF]

Antimicrob Agents Chemother, 2021
In vitro antifungal susceptibility profiling of 32 clinical and environmental Talaromyces marneffei isolates recovered from southern China was performed against olorofim and 7 other systemic antifungals, including amphotericin B, 5-flucytosine, posaconazole, voriconazole, caspofungin, and terbinafine ...
Zhang J, Liu H, Xi L, Chang YC, Kwon-Chung KJ, Seyedmousavi S.   +5 more
europepmc   +4 more sources

Antifungal metabolites, their novel sources, and targets to combat drug resistance. [PDF]

Front Microbiol, 2022
Excessive antibiotic prescriptions as well as their misuse in agriculture are the main causes of antimicrobial resistance which poses a growing threat to public health. It necessitates the search for novel chemicals to combat drug resistance.
Choudhary M, Kumar V, Naik B, Verma A, Saris PEJ, Kumar V, Gupta S.   +6 more
europepmc   +3 more sources

Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans [PDF]

Journal of Antimicrobial Chemotherapy, 2017
Scedosporium species and Lomentospora prolificans are increasing causes of invasive infections in immunocompromised hosts and many isolates are resistant to available antifungals. Our objective was to assess the in vitro potency of F901318, a member of the orotomide class of antifungals, against Scedosporium species and L.
Nathan P Wiederhold
exaly   +3 more sources

In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates [PDF]

Journal of Antimicrobial Chemotherapy, 2017
F901318 is a new antifungal agent with a novel mechanism of action with activity against Aspergillus species. We investigated the in vitro activity of F901318 against a collection of Aspergillus isolates.A total of 213 Aspergillus isolates were used in this study.
Jochem B Buil, Willem J G Melchers, Paul E Verweij   +2 more
exaly   +5 more sources

Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical Aspergillus fumigatus isolates, and review of azole resistance phenotype and genotype epidemiology in China. [PDF]

Antimicrob Agents Chemother, 2023
Triazole resistance in Aspergillus fumigatus is an increasing worldwide problem that causes major challenges in the management of aspergillosis. New antifungal drugs are needed, with novel targets, that are effective in triazole-resistant infection.
Su H, Zhu M, Tsui CK, van der Lee H, Tehupeiory-Kooreman M, Zoll J, Engel T, Li L, Zhu J, Lu Z, Zhang Q, Verweij PE, Deng S.   +12 more
europepmc   +6 more sources

Olorofim demonstrates <i>in vitro</i> activity against <i>Coccidioides</i> species, including isolates against which fluconazole has reduced activity. [PDF]

Antimicrob Agents Chemother
We evaluated the in vitro activity of olorofim against Coccidioides species. Olorofim demonstrated potent in vitro activity against all isolates tested with a minimum inhibitory concentration (MIC) range ≤0.008-0.06 µg/mL and geometric mean MIC of 0.010 ...
Wiederhold NP, Patterson HP, Ferrer D, Garcia V, Thompson GR, Patterson TF.   +5 more
europepmc   +3 more sources

EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs [PDF]

Antimicrobial Agents and Chemotherapy, 2018
ABSTRACT Olorofim is a novel antifungal agent with in vitro activity against Aspergillus and some other molds. Here, we addressed technical aspects for EUCAST olorofim testing and generated contemporary MIC data.
Rasmus Hare Jensen, Maiken Cavling Arendrup   +1 more
exaly   +4 more sources

In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies

Journal of Antimicrobial Chemotherapy, 2019
To investigate the in vitro activity of olorofim (F901318), a novel broad-spectrum antifungal agent, against 150 strains belonging to 16 different cryptic species of Aspergillus by EUCAST and CLSI methodologies.Olorofim, amphotericin B, micafungin, posaconazole and voriconazole were tested against cryptic species belonging to Aspergillus fumigatus ...
Olga Rivero-Menendez, Ana Alastruey-Izquierdo   +1 more
exaly   +3 more sources

Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease. [PDF]

Antimicrob Agents Chemother, 2019
The emergence of azole resistance in Aspergillus fumigatus as well as an increasing frequency of multiresistant cryptic Aspergillus spp. necessitates exploration of new classes of antifungals.
Seyedmousavi S, Chang YC, Law D, Birch M, Rex JH, Kwon-Chung KJ.   +5 more
europepmc   +4 more sources

Drug Discovery and Repurposing for <i>Coccidioides</i>: A Systematic Review. [PDF]

J Fungi (Basel)
<i>Coccidioides immitis</i> and <i>C. posadasii</i> are the causative agents of coccidioidomycosis (CM) or Valley Fever, endemic to the alkaline deserts of North and South America. Clinical treatment of CM is predominantly limited
Saeger S, Lozano S, Wiederhold N, Yu JJ, Lopez-Ribot JL, Hung CY.   +5 more
europepmc   +3 more sources